Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilonacept - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals

Drug Profile

Rilonacept - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals

Alternative Names: Arcalyst; IL-1 Trap; IL-1 Trap - Regeneron; Interleukin-1 Trap - Regeneron; KPL 914; RGN 303

Latest Information Update: 18 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Boston University; Charite - Universitatsmedizin Berlin; Kiniksa Pharmaceuticals; Regeneron Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryopyrin-associated periodic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cryopyrin-associated periodic syndromes
  • Phase III Cardiovascular disorders
  • Phase II Urticaria
  • Phase I/II Systemic scleroderma
  • Discontinued Anaemia; Gout; Juvenile rheumatoid arthritis; Osteoarthritis; Polymyalgia rheumatica; Rheumatoid arthritis

Most Recent Events

  • 12 Dec 2018 Phase-III clinical trials in Cardiovascular disorders in USA (SC) (NCT03737110)
  • 11 Dec 2018 Interim safety and efficacy results from the phase II pilot study released by Kiniksa Pharmaceuticals
  • 11 Dec 2018 Kiniksa Pharmaceuticals completes enrolment in phase-II clinical trials in Cardiovascular disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top